Novel Benzoxazoles Containing 4-Amino-Butanamide Moiety Inhibited LPS-Induced Inflammation by Modulating IL-6 or...

Area of Science:

• Medicinal Chemistry
• Immunology
• Pharmacology

Background:

• Lipopolysaccharide (LPS) triggers inflammatory cytokines, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), leading to inflammatory responses.
• Developing small molecules to suppress these inflammatory cytokines is a crucial strategy for treating inflammatory diseases.

Purpose of the Study:

• To synthesize and evaluate novel 4-amino-N-(4-(benzo[d]oxazol-2-ylamino)phenyl)butanamide derivatives for their potential to suppress inflammatory cytokine production.
• To identify lead compounds with potent anti-inflammatory activity through in vitro and in vivo assessments.

Main Methods:

• Synthesis of 12 novel compounds featuring the 4-amino-N-(4-(benzo[d]oxazol-2-ylamino)phenyl)butanamide core structure.
• In vitro evaluation of inhibitory activity against IL-1β and IL-6 mRNA expression.
• In vivo assessment of anti-inflammatory effects and toxicity using selected compounds (5f and 4d).

Main Results:

• Four synthesized compounds (5d, 5c, 5f, 5m) and intermediate 4d exhibited potent inhibition of IL-1β and IL-6 mRNA expression in vitro.
• Compounds 5f and 4d significantly decreased mRNA levels of IL-1β, IL-6, and TNF-α in vivo.
• No significant hepatotoxicity was observed in the in vivo studies.

Conclusions:

• The synthesized 4-amino-N-(4-(benzo[d]oxazol-2-ylamino)phenyl)butanamide derivatives are effective in suppressing key inflammatory cytokines.
• These novel compounds demonstrate potential as therapeutic agents for inflammatory diseases due to their potent anti-inflammatory effects and favorable safety profile.